Drug Trial Radar · NCT04220515
Inactivated Poliomyelitis Vaccine Made From Sabin Strain
Last checked: Nov 20, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49,731
Actual
Start
Feb 8, 2018
Primary completion
Aug 8, 2019
Study completion Oct 14, 2019
Sponsor
- Lead sponsor
- Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai Center for Disease Control and Prevention
- First posted
- Jan 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 months, up to 3 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study includes both active and passive safety monitoring in large pupulations for the phase IV safety monitoring study of Inactivated Poliomyelitis Vaccine Made From Sabin Strain (sIPV).
Conditions
- Poliomyelitis
Interventions
Inactivated Poliomyelitis Vaccine Made From Sabin StrainBiological
Type I D antigen 30DU;Type II D antigen 32DU;Type III D antigen 45 DU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety monitoringTime frame: 30 days post inoculation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Disease prevention and control center of Shanghai
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.